Skip to main content

Table 2 Adverse events that occurred in at least 10% of patients

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

AE, n (%)

All grade

Grades 1–2

Grade ≥ 3

Pyrexia

52 (91)

41 (72)

11 (19)

Cytokine release syndromea

51 (90)

47 (83)

4 (7)

Thrombocytopenia

28 (49)

15 (26)

13 (23)

Leukopenia

27 (47)

10 (18)

17 (30)

AST increased

22 (39)

10 (18)

12 (21)

Anemia

17 (30)

7 (12)

10 (18)

Hypotension

12 (21)

9 (16)

3 (5)

ALT increased

10 (18)

10 (18)

0

Cough

10 (18)

10 (18)

0

Disseminated intravascular coagulation

10 (18)

9 (16)

1 (2)

Hypocalcemia

9 (16)

7 (12)

2 (4)

Hyponatremia

8 (14)

5 (9)

3 (5)

Dyspnea

6 (11)

6 (11)

0

Nausea

6 (11)

6 (11)

0

  1. ALT alanine aminotransferase, AST aspartate aminotransferase
  2. aCytokine release syndrome assessed using modified criteria by Lee et al. [25]